INDUCTION OF INTERFERON-GAMMA, INTERLEUKIN-4, AND TRANSFORMING GROWTH-FACTOR-BETA IN RATS ORALLY TOLERIZED AGAINST EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS

被引:69
作者
WANG, ZY
LINK, H
LJUNGDAHL, A
HOJEBERG, B
LINK, J
HE, B
QIAO, J
MELMS, A
OLSSON, T
机构
[1] HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT NEUROL,STOCKHOLM,SWEDEN
[2] UNIV TUBINGEN,DEPT NEUROL,W-7400 TUBINGEN,GERMANY
关键词
D O I
10.1006/cimm.1994.1233
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Oral administration of nicotinic acetylcholine receptor (AChR) to Lewis rats prior to myasthenogenic immunization with Torpedo AChR + complete Freund's adjuvant (CFA) results in the prevention of experimental autoimmune myasthenia gravis (EAMG) and the suppression of AChR-specific B cell responses and counteracts the development of AChR-reactive interferon-gamma (IFN-gamma) secreting T cells. To study the involvement of the T helper type 1 (Th1) cell-related lymphokine IFN-gamma, the Th2 cell-related interleukin-4 (IL-4), and transforming growth factor beta (TGF-beta) that suppresses the synthesis of IFN-gamma and IL-4, we used in situ hybridization with complementary DNA oligonucleotide probes to enumerate mononuclear cells (MNC) expressing mRNA for the cytokines IFN-gamma, IL-4, and TGF-beta. Upon in vivo recognition of AChR, popliteal, inguinal, and mesenteric lymph nodes, spleen and thymus of rats with EAMG contained higher levels of IFN-gamma, IL,-4, and TGF-beta mRNA-expressing cells compared to CFA-injected control rats, implicating the involvement in EAMG of AChR-reactive Th1 and Th2 cells in parallel. TGF-beta was also upregulated in EAMG. Oral tolerance to EAMG was characterized by suppression of the levels of MNC expressing IFN-gamma and IL-4, but augmentation of cells expressing TGF-beta. The results suggest that IFN-gamma, IL-4, and TGF-beta are involved in the development of EAMG, and that TGF-beta is important in the induction of oral tolerance to EAMG. (C) 1994 Academic Press, Inc.
引用
收藏
页码:353 / 368
页数:16
相关论文
共 34 条
[11]  
HIGGINS PJ, 1988, J IMMUNOL, V140, P440
[12]  
HOHLFELD R, 1985, J IMMUNOL, V135, P2393
[13]   MYASTHENIC IMMUNOGLOBULIN ACCELERATES ACETYLCHOLINE-RECEPTOR DEGRADATION [J].
KAO, I ;
DRACHMAN, DB .
SCIENCE, 1977, 196 (4289) :527-529
[14]   PRODUCTION OF TRANSFORMING GROWTH-FACTOR-BETA BY HUMAN LYMPHOCYTES-T AND ITS POTENTIAL ROLE IN THE REGULATION OF T-CELL GROWTH [J].
KEHRL, JH ;
WAKEFIELD, LM ;
ROBERTS, AB ;
JAKOWLEW, S ;
ALVAREZMON, M ;
DERYNCK, R ;
SPORN, MB ;
FAUCI, AS .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 163 (05) :1037-1050
[15]  
KEHRL JH, 1986, J IMMUNOL, V137, P3855
[16]  
KEHRL JH, 1991, J IMMUNOL, V146, P4016
[17]   ROLE OF COMPLEMENT IN PATHOGENESIS OF EXPERIMENTAL AUTO-IMMUNE MYASTHENIA-GRAVIS [J].
LENNON, VA ;
SEYBOLD, ME ;
LINDSTROM, JM ;
COCHRANE, C ;
ULEVITCH, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 1978, 147 (04) :973-983
[18]  
LIDER O, 1989, J IMMUNOL, V142, P748
[19]   MYASTHENIA-GRAVIS [J].
LINDSTROM, J ;
SHELTON, D ;
FUJII, Y .
ADVANCES IN IMMUNOLOGY, 1988, 42 :233-284
[20]   ACETYLCHOLINE-RECEPTOR REACTIVE T-CELLS AND B-CELLS IN MYASTHENIA-GRAVIS AND CONTROLS [J].
LINK, H ;
OLSSON, O ;
SUN, JB ;
WANG, WZ ;
ANDERSSON, G ;
EKRE, HP ;
BRENNER, T ;
ABRAMSKY, O ;
OLSSON, T .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (06) :2191-2196